Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Keywords: 
Bruton tyrosine kinase (BTK)
Mantle cell lymphoma (MCL)
Acalabrutinib
Clinical data
Issue Date: 
2019
Publisher: 
Springer Science and Business Media LLC
ISSN: 
0887-6924
Note: 
This article is licensed under a Creative Commons Attribution 4.0 International License
Citation: 
Wang, M. (Michael); Rule, S. (Simon); Zinzani, P.L. (P.L.); et al. "Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma". Leukemia. 33, 2019, 2762 - 2766
Abstract
Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up. Eligibility criteria and study design were published previously (Supplementary methods) [1]. Analysis of minimal residual disease (MRD) was conducted after complete response (CR) or partial response (PR) was achieved using the quantitative ClonoSEQ next-generation sequencing (5 × 10−6 ) assay (Adpative Biotechnologies, Seattle, WA, USA) in consenting patients with available paired archival tumor and whole blood samples. Data are updated as of February 12, 2018.

Files in This Item:
Thumbnail
File
s41375-019-0575-9.pdf
Description
Size
341.65 kB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.